Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Schwab US Dividend Equity ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.53 (market cap $12.58B), while Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 8.8× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Schwab US Dividend Equity ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| HALO | SCHD | |
|---|---|---|
Market Cap | $12.58B | $110.56B |
Volume | 2,179,278 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $115.22 | $35.21 |
52-Week Low | $61.63 | $26.44 |
Typical Hold Time | 1 Days | 62 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SCHD trades at $33.09, up 1.35% with a bullish technical signal despite mixed moving averages. Recent news highlights its outperformance versus the S&P 500 in 2026 and dividend growth, though the ETF faces pressure from rising interest rates. Support sits at $32-$33, with resistance at $33-$34. The RSI readings are neutral, while ADX signals conflicting trend strength.
Outlook: SCHD offers income growth and lower fees, appealing for dividend investors, but interest rate sensitivity and defensive tilts pose risks. The ETF's rule-based approach may miss high-growth stocks, as seen with Broadcom. Near-term performance hinges on macroeconomic trends and dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
